Evidence map›Paper›PMID 37308680›Full record

ArticleMolecular psychiatry2023

Ethanol inhibits dopamine uptake via organic cation transporter 3: Implications for ethanol and cocaine co-abuse.

N J Clauss, F P Mayer, W A Owens, M Vitela, K M Clarke, M A Bowman, R E Horton, D Gründemann, D Schmid, M Holy and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Dopamine Pharmacodynamics: New Insights.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

N J Clauss *Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.ORCID 0000-0003-1503-3836
F P Mayer *Center for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria.ORCID 0000-0001-9837-8973
W A OwensDepartment of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
M VitelaDepartment of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
K M ClarkeDepartment of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
M A BowmanDepartment of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
R E HortonDepartment of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
D GründemannDepartment of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931, Cologne, Germany.ORCID 0000-0003-0914-0299
D SchmidCenter for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria.ORCID 0000-0002-2225-9836
M HolyCenter for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria.
G G GouldDepartment of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
W KoekDepartment of Cell Systems and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.ORCID 0000-0002-9049-9719
H H SitteCenter for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria.ORCID 0000-0002-1339-7444
L C DawsDepartment of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA. daws@uthscsa.edu.ORCID 0000-0002-6793-791X
The University of Texas Health Science Center at San Antonio · USMedical University of Vienna · ATUniversity of Cologne · DEUniversity of Copenhagen · DK

Funding

Role of the serotonin transporter and organic cation transporter 3 in serotonergic modulation of emotion-regulating circuitryR01MH093320 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAWS, LYNETTE C, TONEY, GLENN M · 2012 to 2023
$6.3M
Training in Drug Abuse Research: Behavior and NeurobiologyT32DA031115 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHARLES P FRANCE · 2011 to 2026
$5.2M
Exploring a role for organic transporter 3 in the mechanism of action of drugs of abuseR21DA046044 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAWS, LYNETTE C, KOEK, WOUTER · 2018 to 2019
$419k
Targeting organic cation transporter 3 in treatment of substance use disordersU18DA052527 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAWS, LYNETTE C · 2020 to 2020
$296k
Austrian Science Fund FWF P 34670NIDA NIH HHS R21 DA046044NIDA NIH HHS T32 DA031115NIDA NIH HHS U18 DA052527NIMH NIH HHS R01 MH093320
6 · The paper itself

Abstract

Concurrent cocaine and alcohol use is among the most frequent drug combination, and among the most dangerous in terms of deleterious outcomes. Cocaine increases extracellular monoamines by blocking dopamine (DA), norepinephrine (NE) and serotonin (5-HT) transporters (DAT, NET and SERT, respectively). Likewise, ethanol also increases extracellular monoamines, however evidence suggests that ethanol does so independently of DAT, NET and SERT. Organic cation transporter 3 (OCT3) is an emergent key player in the regulation of monoamine signaling. Using a battery of in vitro, in vivo electrochemical, and behavioral approaches, as well as wild-type and constitutive OCT3 knockout mice, we show that ethanol's actions to inhibit monoamine uptake are dependent on OCT3. These findings provide a novel mechanistic basis whereby ethanol enhances the neurochemical and behavioral effects of cocaine and encourage further research into OCT3 as a target for therapeutic intervention in the treatment of ethanol and ethanol/cocaine use disorders.

Indexed as

CocaineCocaine-Related DisordersAnimalsCarrier ProteinsCationsDopamineDopamine Plasma Membrane Transport ProteinsEthanolMiceMice, KnockoutSerotoninSerotonin Plasma Membrane Transport ProteinsCarrier ProteinsCationsCocaineDopamineDopamine Plasma Membrane Transport ProteinsEthanolSerotoninSerotonin Plasma Membrane Transport Proteins

Identifiers

PMID37308680
PMCPMC10615754
OpenAlexW4380422036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.